Last week (August 3rd to August 7th), a group of pharmaceutical companies received a pile of research from institutions.

Pharmaceutical Network Industry Dynamics Last week (August 3 to August 7), the enthusiasm of institutional research listed companies remains, and a number of listed companies by more than 100 institutions intensive research, causing widespread concern in the market.
, 29 listed companies received surveys from various institutions, including fund companies, securities companies, overseas institutions, sunshine private equity firms and insurance companies, according to Tonghuashun.
from the industry point of view, these 29 stocks are mainly stacked in the pharmaceutical biology, chemical, electronics and other three industries.
the pharmaceutical and biological industry, Dongcheng Pharmaceuticals has obtained more than 10 institutions to focus on research.
August 7, a total of 220 people, including Castrol Fund, Guangfa Fund, Ruiyuan Fund and other institutions, participated in a conference call with Dongcheng Pharmaceuticals.
It is understood that Dongcheng Pharmaceuticals received a large number of institutions to focus on research, on the one hand, on the one hand, "the United States will carry out heparin 45.6 trillion units of reserves" of the news, on the other hand, and the company disclosed the semi-annual report.
recently, the U.S. Biomedical Advanced Research and Development Agency updated and issued a tender for THE purchase of API, indicating that the U.S. plans to purchase 36 API products, the implementation period is expected to be 5 years.
of which heparin alone requires 45.6 trillion units, and another 867.2 trillion units are optional.
was affected by the news, Dongcheng Pharmaceuticals' shares rose 10.50 percent last week.
Public information shows that The business of The owner of Dongcheng Pharmaceuticals is the research and development, production and sales of heparin sodium API, cartilage sulphate, products covering heparin sodium API, heparin calcium API, cartilage sulfate and velvet and other injections.
the research process, in response to the above-mentioned news asked about the future price trend of Dongcheng Pharmaceuticals, the impact of this reserve on the company and so on.
In this regard, Dongcheng Pharmaceuticals said that China's annual export volume of about 20 trillion units, the United States procurement plan, the demand for the entire heparin pull is very large;
addition, Dongcheng Pharmaceuticals also disclosed the nuclear drug research situation.
Of these, "Yu 188" is undergoing Phase 2b clinical, as of the end of June has entered the group of 57 patients, is currently in accordance with the plan to advance, and strive to complete the patient into the group at an early date;
According to Dongcheng Pharmaceuticals' 2020 semi-annual report released on August 6, the company achieved revenue of 1,646 million yuan in the first half of 2020, an increase of 24.08 percent over the previous year, and a net profit of 219 million yuan, an increase of 23.05 percent year-on-year.
said that the first half of the API business is basically unaffected, but as the outbreak in Europe and the United States gradually increased, bringing some uncertainty.
the preparation business, which was affected by the outbreak in the first half of the year, maintained double-digit growth and has now returned to the momentum of previous years.
addition to Dongcheng Pharmaceuticals, Beida Pharmaceuticals, Kelly Tai, Tongze Medical, Huahua Pharmaceuticals, Hanyu Pharmaceuticals and other 6 pharmaceutical and biological companies have also gained a number of research institutions.
from these pharmaceutical companies have disclosed the first half of the performance of the situation, the results are also relatively bright.
, Bayda Pharmaceuticals' operating income in the first half of 2020 was 952 million yuan, up 24.92 percent year-on-year, with a net profit of 144 million yuan, up 64.65 percent year-on-year.
.